Faced with the challenge of delivering mRNA into the correct cell, mRNA carriers have long been unable to maximize mRNA as a therapeutic tool capable of guiding cells to generate disease-fighting proteins. Innorna developed the proprietary diversity-oriented LNP platform for safely and effectively deliver the mRNA into the correct cells and commercializing this innovative technology. This enables a wide range of potential prophylactic and therapeutic strategies that we are using to advance a diversified portfolio of mRNA medicine pipelines．
The core elements and coding sequences of mRNA determine the stability of its binding to ribosomes, thereby affecting the efficiency and duration of protein translation. Through rational sequence design and optimization, we have identified the optimal ribosome-binding sequences to enable more efficient and long-lasting protein translation.
